KEGG   DRUG: Ledipasvir - sofosbuvir mixtHelp
Entry
D10578            Mixture   Drug                                   

Name
Ledipasvir - sofosbuvir mixt;
Harvoni (TN)
Product
Component
Ledipasvir [DR:D10442], Sofosbuvir [DR:D10366]
Remark
Therapeutic category: 6250
ATC code: J05AP51
Product: D10578<JP/US>
Efficacy
Antiviral
  Disease
Chronic hepatitis C virus infection [DS:H00413]
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AP Antivirals for treatment of HCV infections
     J05AP51 Sofosbuvir and ledipasvir
      D10578  Ledipasvir - sofosbuvir mixt <JP/US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-hepatitis C (HCV) Agents, Direct Acting
   Ledipasvir/Sofosbuvir
    D10578  Ledipasvir - sofosbuvir mixt
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D10578  Ledipasvir - sofosbuvir mixt
Antiinfectives [br08350.html]
 Antivirals
  D10578
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D10578
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10578
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10578
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10578
BRITE hierarchy
Other DBs
PubChem: 254741540
ChEBI: 85082
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system